Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City

Clinical Infectious Diseases

Volumn 54, Issue 9, 2012, Pages 1287-1295

  Anger, Holly A ^a   Proops, Douglas ^a   Harris, Tiffany G ^a   Li, Jiehui ^a   Kreiswirth, Barry N ^b   Shashkina, Elena ^b   Ahuja, Shama D ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; DISEASE REGISTRY; FOLLOW UP; HUMAN; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONTACT TRACING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; ISONIAZID; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NEW YORK CITY; NUMBERS NEEDED TO TREAT; PREVALENCE; RETROSPECTIVE STUDIES; RIFAMPIN; TUBERCULIN TEST; TUBERCULOSIS; YOUNG ADULT;

EID: 84859748105     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis029     Document Type: Article

References (36)

1. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172:1169-227.
2. Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010; 36:925-49.
3. Menzies D, Tannenbaum TN, FitzGerald JM. Tuberculosis: 10. Prevention. CMAJ 1999; 161:717-24. (Pubitemid 29446107)
4. Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003; 7:S384-90. (Pubitemid 38004714)
5. Reichler MR, Reves R, Bur S, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA 2002; 287:991-5. (Pubitemid 34252056)
6. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970; 26:28-106.
7. Veening GJ. Long term isoniazid prophylaxis: controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc 1968; 41:169-71.
8. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49:1-51.
9. Mount FW, Ferebee SH. Preventive effects of isoniazid in the treatment of primary tuberculosis in children. N Engl J Med 1961; 265:713-21.
10. Mount FW, Ferebee SH. The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis 1962; 85:821-7.
11. Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis 1963; 88:161-75.
12. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979; 119:827-30.
13. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000; 162:2033-8. (Pubitemid 32051659)
14. Clinical policies and protocols: Bureau of Tuberculosis Control. 4th ed. New York, NY: New York City Department of Health and Mental Hygiene, 2008.
15. Recommendations from the National Tuberculosis Controllers Association and the Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. MMWR Recomm Rep 2005; 54:1-47.
16. Poulsen A. Some clinical features of tuberculosis. 1. Incubation period. Acta Tuberc Scand 1950; 24:311-46.
17. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep 1997; 46:1-55.
18. Clark CM, Driver CR, Munsiff SS, et al. Universal genotyping in tuberculosis control program, New York City, 2001-2003. Emerg Infect Dis 2006; 12:719-24. (Pubitemid 43726843)
19. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17:873-90. (Pubitemid 28185166)
20. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318:1728-33.
21. Becerra MC, Pachao-Torreblanca IF, Bayona J, et al. Expanding tuberculosis case detection by screening household contacts. Public Health Rep 2005; 120:271-7. (Pubitemid 40631537)
22. Sia IG, Orillaza RB, St Sauver JL, et al. Tuberculosis attributed to household contacts in the Philippines. Int J Tuberc Lung Dis 2010; 14: 122-5.
23. Moran-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM. Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis 2010; 14:1112-9.
24. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168:443-7. (Pubitemid 37046873)
25. Horsburgh CR Jr, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010; 137:401-9.
26. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3:847-50. (Pubitemid 29488035)
27. World Health Organization. Implementing the Stop TB Strategy: a handbook for national tuberculosis control programmes. Geneva, Switzerland: World Health Organization, 2008. Vol. WHO/HTM/TB/2008.401.
28. Tulsky JP, Pilote L, Hahn JA, et al. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med 2000; 160:697-702. (Pubitemid 30140420)
29. White MC, Tulsky JP, Reilly P, McIntosh HW, Hoynes TM, Goldenson J. A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail. Int J Tuberc Lung Dis 1998; 2: 506-12. (Pubitemid 28326316)
30. Malotte CK, Hollingshead JR, Larro M. Incentives vs outreach workers for latent tuberculosis treatment in drug users. Am J Prev Med 2001; 20:103-7. (Pubitemid 32106944)
31. Snider DE Jr. Bacille Calmette-Guerin vaccinations and tuberculin skin tests. JAMA 1985; 253:3438-9. (Pubitemid 15056654)
32. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immunebased diagnosis of tuberculosis. Lancet 2000; 356:1099-104.
33. Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010; 59:1-25.
34. Yoshiyama T, Harada N, Higuchi K, Sekiya Y, Uchimura K. Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. Int J Tuberc Lung Dis 2010; 14:819-27.
35. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-70. (Pubitemid 351717577)
36. Sterling T. PREVENT TB: results of a 12-dose, once weekly treatment of LTBI. In: American Thoracic Society 2011 International Conference. Denver, Colorado.